Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 162 (Denosumab) in Postmenopausal Women With Low Bone Mineral Density
NCT00043186Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2002
- Primary completion
- Apr 2007
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 2, randomised, double-blind trial of denosumab in low bone mineral density (9 arms), sponsored by Amgen. Primary endpoint: Lumbar Spine Bone Mineral Density Percent Change From Baseline at 12 months. Started May 2002; status: completed.
02
Drugs
denosumab
03
Conditions
low bone mineral density
Beyond the preview
Go deeper on NCT00043186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00043186.